Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen- independent mechanisms

International Journal of Cancer

Volumn 77, Issue 2, 1998, Pages 251-256

  Link, Brian K ^a   Kostelny, Sheri A ^b   Cole, Michael S ^b   Fusselman, William P ^a   Tso, J Yun ^b   Weiner, George J ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b PROTEIN DESIGN LABS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY;

ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CYTOTOXICITY TEST; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; RAJI CELL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; B-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MICE; RECEPTORS, FC; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0031806536     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980717)77:2<251::AID-IJC14>3.0.CO;2-E     Document Type: Article

References (21)

1. ALEGRE, M.L., COLLINS, A.M., PULITO, V.L., BROSIUS, R.A., OLSON, W.C., ZIVIN, R.A., KNOWLES, R., THISTLETHWAITE, J.R., JOLLIFFE, L.K., and BLUESTONE, J.A., Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J. Immunol. 148, 3461-3468 (1992).
2. BELANI, R. and WEINER, G.J., T cell activation and cytokine production in anti-CD3 bispecific antibody therapy. J. Hematother., 4, 395-402 (1995).
3. CANEVARI, S., MEZZANZANICA, D., MAZZONI, A., NEGRI, D.R., RAMAKRISHNA, V., BOLHUIS, R.L., COLNAGHI, M.I. and BOLIS, G., Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J. Hematother., 4, 423-427 (1995).
4. CARTER, P., RIDGWAY, J. and ZHU, Z., Toward the production of bispecific antibody fragments for clinical applications. J. Hematother., 4, 463-470 (1995).
5. DE GAST, G.C., HAAGEN, I.A., VAN HOUTEN, A.A., KLEIN, S.C., DUITS, A.J., DE WEGER, R.A., VROOM, T.M., CLARK, M.R., PHILLIPS, J., VAN DIJK, A.J., DE LAU, W. and BAST, B.J., CD8T cell activation after intravenous administration of CD3 × CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol. Immunother., 40, 390-396 (1995a).
6. DE GAST, G.C., VAN HOUTEN, A.A., HAAGEN, I.A., KLEIN, S., DE WEGER, R.A., VAN DIJK, A., PHILLIPS, J., CLARK, M. and BAST, B.J., Clinical experience with CD3 × CD 19 bispecific antibodies in patients with B cell malignancies. J. Hematother., 4, 433-437 (1995b).
7. GINGRICH, R.D., DAHLE, C.E., HOSKINS, K.F. and SENNEFF, M.J., Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood, 75, 2375-2387 (1990).
8. HAAGEN, I.A., GEERARS, A.J., DE LAU, W.B., CLARK, M.R., VAN DE GRIEND, R.J., BAST, B.J. and DE GAST, B.C., Killing of autologous B-lineage malignancy using CD3 × CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood, 84, 556-563 (1994).
9. KOSTELNY, S.K., COLE, M.S. and TSO, J.Y., Formation of a bispecific antibody by the use of leucine zippers. J. Immunol., 148, 1547-1553 (1992).
10. KROESEN, B.J., BARKER, A., VAN LIER, R.A.W., THE, H.T. and DE LEIJ, L., Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28. Cancer Res., 55, 4409-4415 (1995).
11. KROESEN, B.J., BUTER, J., SLEIJFER, D.T., JANSSEN, R.A., VAN DER GRAAF, W.T., THE, T.H., DE LEIJ, L. and MULDER, N.H., Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Brit. J. Cancer, 70, 652-661 (1994).
12. LINK, B.K. and WEINER, G.J., Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B cells. Blood, 81, 3343-3349 (1993).
13. MCLAUGHLIN, P. and 14 OTHERS, IDEC-C2B8 anti-CD20 antibody: final report on a phase III pivotal trial in patients with relapsed low grade or follicular lymphoma. Blood, 88, 90a (1996).
14. QUEEN, C., SCHNEIDER, W.P., SELICK, H.E., PAYNE, P.W., LANDOLFI, N.F., DUNCAN, J.F., AVDALOVIC, N.M., LEVITT, M., JUNGHANS, R.P. and WALDMANN, T.A., A humanized antibody that binds to the interleukin 2 receptor. Proc. nat. Acad. Sci. (Wash.), 86, 10029-10033 (1989).
15. RENNER, C., JUNG, W., SAHIN, U., DENFELD, R., POHL, C., TRUMPER, L., HARTMANN, F., DIEHL, V., VAN LIER, R. and PFREUNDSCHUH, M., Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science, 264, 833-835 (1994).
16. SEGAL, D.M., QIAN, J.H., MEZZANZANICA, D., GARRIDO, M.A., TITUS, J.A., ANDREW, S.M., GEORGE, A.J., JOST, C.R., PEREZ, P. and WUNDERLICH, J.R., Targeting of anti-tumor responses with bispecific antibodies. Immunobiology, 185, 390-402 (1992).
17. 2 in ovarian carcinoma patients. Int. J. Cancer, 66, 477-483 (1996).
18. 2 targeted to the human IL-2 receptor. J. Hematother., 4, 389-394 (1995).
19. WEINER, G.J. and DE GAST, G.C., Bispecific monoclonal antibody therapy of B-cell malignancy. Leukemia Lymphoma, 16, 199-207 (1995).
20. WEINER, G.J., KOSTELNY, S.A., HILLSTROM, J.R., COLE, M.S., LINK, B.K., WANG, S.L. and TSO, J.Y., The role of T cell activation in anti-CD3 × antitumor bispecific antibody therapy. J. Immunol., 152, 2385-2392 (1994).
21. ZHU, Z. and CARTER, P., Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. J. Immunol., 155, 1903-1910 (1995).